6vfi › Citations

Tailored design of protein nanoparticle scaffolds for multivalent presentation of viral glycoprotein antigens.

<div class='caption-title'>De novo design of protein nanoparticles tailored for multivalent antigen presentation.</div>
<div class='caption-title'>Computational docking and design of trimers for fusion to a specific viral glycoprotein.</div>
<div class='caption-title'>Top rows, design models. Middle rows, SEC chromatograms and calculated molecular weights from SEC-MALS. Bottom rows, comparisons between experimental SAXS data and scattering profiles calculated from design models. (a) 1na0C3_2. (b) 3ltjC3_1v2. (c) 3ltjC3_11. (d) HR04C3_5v2. (e) T33_dn2. (f) T33_dn10. (g) O43_dn18. (h) I53_dn5.</div>
Ueda G, Antanasijevic A, Fallas JA, Sheffler W, Copps J, Ellis D, Hutchinson GB, Moyer A, Yasmeen A, Tsybovsky Y, Park YJ, Bick MJ, Sankaran B, Gillespie RA, Brouwer PJ, Zwart PH, Veesler D, Kanekiyo M, Graham BS, Sanders RW, Moore JP, Klasse PJ, Ward AB, King NP, Baker D
OpenAccess logo Elife 9 (2020)
Related entries: 6v8e, 6veh, 6vfh, 6vfj

Cited: 69 times
EuropePMC logo PMID: 32748788

Abstract

Vaccines train the immune system to recognize a specific virus or bacterium so that the body can be better prepared against these harmful agents. To do so, many vaccines contain viral molecules called glycoproteins, which are specific to each type of virus. Glycoproteins that sit at the surface of the virus can act as ‘keys’ that recognize and unlock the cells of certain organisms, leading to viral infection. To ensure a stronger immune response, glycoproteins in vaccines are often arranged on a protein scaffolding which can mimic the shape of the virus of interest and trigger a strong immune response. Many scaffoldings, however, are currently made from natural proteins which cannot always display viral glycoproteins. Here, Ueda, Antanasijevic et al. developed a method that allows for the design of artificial proteins which can serve as scaffolding for viral glycoproteins. This approach was tested using three viruses: influenza, HIV, and RSV – a virus responsible for bronchiolitis. The experiments showed that in each case, the relevant viral glycoproteins could attach themselves to the scaffolding. These structures could then assemble themselves into vaccine particles with predicted geometrical shapes, which mimicked the virus and maximized the response from the immune system. Designing artificial scaffolding for viral glycoproteins gives greater control over vaccine design, allowing scientists to manipulate the shape of vaccine particles and test the impact on the immune response. Ultimately, the approach developed by Ueda, Antanasijevic et al. could lead to vaccines that are more efficient and protective, including against viruses for which there is currently no suitable scaffolding.

Reviews citing this publication (27)

  1. Designing spatial and temporal control of vaccine responses. Roth GA, Picece VCTM, Ou BS, Luo W, Pulendran B, Appel EA. Nat Rev Mater 7 174-195 (2022)
  2. Virus-Like Particles: Revolutionary Platforms for Developing Vaccines Against Emerging Infectious Diseases. Tariq H, Batool S, Asif S, Ali M, Abbasi BH. Front Microbiol 12 790121 (2021)
  3. Protein Assembly by Design. Zhu J, Avakyan N, Kakkis A, Hoffnagle AM, Han K, Li Y, Zhang Z, Choi TS, Na Y, Yu CJ, Tezcan FA. Chem Rev 121 13701-13796 (2021)
  4. Platforms for Production of Protein-Based Vaccines: From Classical to Next-Generation Strategies. Cid R, Bolívar J. Biomolecules 11 1072 (2021)
  5. Protein engineering strategies for rational immunogen design. Caradonna TM, Schmidt AG. NPJ Vaccines 6 154 (2021)
  6. Adenovirus-based vaccines-a platform for pandemic preparedness against emerging viral pathogens. Coughlan L, Kremer EJ, Shayakhmetov DM. Mol Ther 30 1822-1849 (2022)
  7. New Technologies for Influenza Vaccines. Rockman S, Laurie KL, Parkes S, Wheatley A, Barr IG. Microorganisms 8 E1745 (2020)
  8. Peptide-based supramolecular vaccine systems. O'Neill CL, Shrimali PC, Clapacs ZE, Files MA, Rudra JS. Acta Biomater 133 153-167 (2021)
  9. Strategies for induction of HIV-1 envelope-reactive broadly neutralizing antibodies. Williams WB, Wiehe K, Saunders KO, Haynes BF. J Int AIDS Soc 24 Suppl 7 e25831 (2021)
  10. Influenza Neuraminidase Characteristics and Potential as a Vaccine Target. Creytens S, Pascha MN, Ballegeer M, Saelens X, de Haan CAM. Front Immunol 12 786617 (2021)
  11. Engineering Self-Assembling Protein Nanoparticles for Therapeutic Delivery. Olshefsky A, Richardson C, Pun SH, King NP. Bioconjug Chem 33 2018-2034 (2022)
  12. Nano toolbox in immune modulation and nanovaccines. Azharuddin M, Zhu GH, Sengupta A, Hinkula J, Slater NKH, Patra HK. Trends Biotechnol 40 1195-1212 (2022)
  13. Immune imprinting and next-generation coronavirus vaccines. Huang CQ, Vishwanath S, Carnell GW, Chan ACY, Heeney JL. Nat Microbiol 8 1971-1985 (2023)
  14. Virus-like particles against infectious disease and cancer: guidance for the nano-architect. Hills RA, Howarth M. Curr Opin Biotechnol 73 346-354 (2022)
  15. Anti-SARS-CoV-1 and -2 nanobody engineering towards avidity-inspired therapeutics. Obeng EM, Dzuvor CKO, Danquah MK. Nano Today 42 101350 (2022)
  16. Protein engineering responses to the COVID-19 pandemic. Hsieh CL, McLellan JS. Curr Opin Struct Biol 74 102385 (2022)
  17. Aptamers as promising nanotheranostic tools in the COVID-19 pandemic era. Dzuvor CKO, Tettey EL, Danquah MK. Wiley Interdiscip Rev Nanomed Nanobiotechnol 14 e1785 (2022)
  18. Structure-based design of novel polyhedral protein nanomaterials. Khmelinskaia A, Wargacki A, King NP. Curr Opin Microbiol 61 51-57 (2021)
  19. Supramolecular assembly of protein building blocks: from folding to function. Kim NH, Choi H, Shahzad ZM, Ki H, Lee J, Chae H, Kim YH. Nano Converg 9 4 (2022)
  20. Targeting Viral Surface Proteins through Structure-Based Design. Narkhede YB, Gonzalez KJ, Strauch EM. Viruses 13 1320 (2021)
  21. Bioengineering Strategies for Developing Vaccines against Respiratory Viral Diseases. Iyer S, Yadav R, Agarwal S, Tripathi S, Agarwal R. Clin Microbiol Rev 35 e0012321 (2022)
  22. Bringing immunofocusing into focus. Musunuri S, Weidenbacher PAB, Kim PS. NPJ Vaccines 9 11 (2024)
  23. Nanoparticle delivery systems for substance use disorder. Kasina V, Mownn RJ, Bahal R, Sartor GC. Neuropsychopharmacology 47 1431-1439 (2022)
  24. Vaccination Strategies Based on Bacterial Self-Assembling Proteins as Antigen Delivery Nanoscaffolds. Lamontagne F, Khatri V, St-Louis P, Bourgault S, Archambault D. Vaccines (Basel) 10 1920 (2022)
  25. Influence of glycosylation on the immunogenicity and antigenicity of viral immunogens. Newby ML, Allen JD, Crispin M. Biotechnol Adv 70 108283 (2024)
  26. Targeting neuraminidase: the next frontier for broadly protective influenza vaccines. Wu NC, Ellebedy AH. Trends Immunol 45 11-19 (2024)
  27. Advanced Vaccine Design Strategies against SARS-CoV-2 and Emerging Variants. Zhang J, Xia Y, Liu X, Liu G. Bioengineering (Basel) 10 148 (2023)

Articles citing this publication (42)

  1. Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2. Walls AC, Fiala B, Schäfer A, Wrenn S, Pham MN, Murphy M, Tse LV, Shehata L, O'Connor MA, Chen C, Navarro MJ, Miranda MC, Pettie D, Ravichandran R, Kraft JC, Ogohara C, Palser A, Chalk S, Lee EC, Guerriero K, Kepl E, Chow CM, Sydeman C, Hodge EA, Brown B, Fuller JT, Dinnon KH, Gralinski LE, Leist SR, Gully KL, Lewis TB, Guttman M, Chu HY, Lee KK, Fuller DH, Baric RS, Kellam P, Carter L, Pepper M, Sheahan TP, Veesler D, King NP. Cell 183 1367-1382.e17 (2020)
  2. Quadrivalent influenza nanoparticle vaccines induce broad protection. Boyoglu-Barnum S, Ellis D, Gillespie RA, Hutchinson GB, Park YJ, Moin SM, Acton OJ, Ravichandran R, Murphy M, Pettie D, Matheson N, Carter L, Creanga A, Watson MJ, Kephart S, Ataca S, Vaile JR, Ueda G, Crank MC, Stewart L, Lee KK, Guttman M, Baker D, Mascola JR, Veesler D, Graham BS, King NP, Kanekiyo M. Nature 592 623-628 (2021)
  3. CD8+ T cells specific for conserved coronavirus epitopes correlate with milder disease in COVID-19 patients. Mallajosyula V, Ganjavi C, Chakraborty S, McSween AM, Pavlovitch-Bedzyk AJ, Wilhelmy J, Nau A, Manohar M, Nadeau KC, Davis MM. Sci Immunol 6 eabg5669 (2021)
  4. SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity. Joyce MG, Chen WH, Sankhala RS, Hajduczki A, Thomas PV, Choe M, Martinez EJ, Chang WC, Peterson CE, Morrison EB, Smith C, Chen RE, Ahmed A, Wieczorek L, Anderson A, Case JB, Li Y, Oertel T, Rosado L, Ganesh A, Whalen C, Carmen JM, Mendez-Rivera L, Karch CP, Gohain N, Villar Z, McCurdy D, Beck Z, Kim J, Shrivastava S, Jobe O, Dussupt V, Molnar S, Tran U, Kannadka CB, Soman S, Kuklis C, Zemil M, Khanh H, Wu W, Cole MA, Duso DK, Kummer LW, Lang TJ, Muncil SE, Currier JR, Krebs SJ, Polonis VR, Rajan S, McTamney PM, Esser MT, Reiley WW, Rolland M, de Val N, Diamond MS, Gromowski GD, Matyas GR, Rao M, Michael NL, Modjarrad K. Cell Rep 37 110143 (2021)
  5. Designed proteins assemble antibodies into modular nanocages. Divine R, Dang HV, Ueda G, Fallas JA, Vulovic I, Sheffler W, Saini S, Zhao YT, Raj IX, Morawski PA, Jennewein MF, Homad LJ, Wan YH, Tooley MR, Seeger F, Etemadi A, Fahning ML, Lazarovits J, Roederer A, Walls AC, Stewart L, Mazloomi M, King NP, Campbell DJ, McGuire AT, Stamatatos L, Ruohola-Baker H, Mathieu J, Veesler D, Baker D. Science 372 eabd9994 (2021)
  6. Multivalent designed proteins neutralize SARS-CoV-2 variants of concern and confer protection against infection in mice. Hunt AC, Case JB, Park YJ, Cao L, Wu K, Walls AC, Liu Z, Bowen JE, Yeh HW, Saini S, Helms L, Zhao YT, Hsiang TY, Starr TN, Goreshnik I, Kozodoy L, Carter L, Ravichandran R, Green LB, Matochko WL, Thomson CA, Vögeli B, Krüger A, VanBlargan LA, Chen RE, Ying B, Bailey AL, Kafai NM, Boyken SE, Ljubetič A, Edman N, Ueda G, Chow CM, Johnson M, Addetia A, Navarro MJ, Panpradist N, Gale M, Freedman BS, Bloom JD, Ruohola-Baker H, Whelan SPJ, Stewart L, Diamond MS, Veesler D, Jewett MC, Baker D. Sci Transl Med 14 eabn1252 (2022)
  7. Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens. Antanasijevic A, Ueda G, Brouwer PJM, Copps J, Huang D, Allen JD, Cottrell CA, Yasmeen A, Sewall LM, Bontjer I, Ketas TJ, Turner HL, Berndsen ZT, Montefiori DC, Klasse PJ, Crispin M, Nemazee D, Moore JP, Sanders RW, King NP, Baker D, Ward AB. PLoS Pathog 16 e1008665 (2020)
  8. Polyclonal antibody responses to HIV Env immunogens resolved using cryoEM. Antanasijevic A, Sewall LM, Cottrell CA, Carnathan DG, Jimenez LE, Ngo JT, Silverman JB, Groschel B, Georgeson E, Bhiman J, Bastidas R, LaBranche C, Allen JD, Copps J, Perrett HR, Rantalainen K, Cannac F, Yang YR, de la Peña AT, Rocha RF, Berndsen ZT, Baker D, King NP, Sanders RW, Moore JP, Crotty S, Crispin M, Montefiori DC, Burton DR, Schief WR, Silvestri G, Ward AB. Nat Commun 12 4817 (2021)
  9. Targeting HIV Env immunogens to B cell follicles in nonhuman primates through immune complex or protein nanoparticle formulations. Martin JT, Cottrell CA, Antanasijevic A, Carnathan DG, Cossette BJ, Enemuo CA, Gebru EH, Choe Y, Viviano F, Fischinger S, Tokatlian T, Cirelli KM, Ueda G, Copps J, Schiffner T, Menis S, Alter G, Schief WR, Crotty S, King NP, Baker D, Silvestri G, Ward AB, Irvine DJ. NPJ Vaccines 5 72 (2020)
  10. Immunofocusing and enhancing autologous Tier-2 HIV-1 neutralization by displaying Env trimers on two-component protein nanoparticles. Brouwer PJM, Antanasijevic A, de Gast M, Allen JD, Bijl TPL, Yasmeen A, Ravichandran R, Burger JA, Ozorowski G, Torres JL, LaBranche C, Montefiori DC, Ringe RP, van Gils MJ, Moore JP, Klasse PJ, Crispin M, King NP, Ward AB, Sanders RW. NPJ Vaccines 6 24 (2021)
  11. Immunogenicity and Protective Efficacy of a Highly Thermotolerant, Trimeric SARS-CoV-2 Receptor Binding Domain Derivative. Malladi SK, Patel UR, Rajmani RS, Singh R, Pandey S, Kumar S, Khaleeq S, van Vuren PJ, Riddell S, Goldie S, Gayathri S, Chakraborty D, Kalita P, Pramanick I, Agarwal N, Reddy P, Girish N, Upadhyaya A, Khan MS, Kanjo K, Bhat M, Mani S, Bhattacharyya S, Siddiqui S, Tyagi A, Jha S, Pandey R, Tripathi S, Dutta S, McAuley AJ, Singanallur NB, Vasan SS, Ringe RP, Varadarajan R. ACS Infect Dis 7 2546-2564 (2021)
  12. Computational design of mechanically coupled axle-rotor protein assemblies. Courbet A, Hansen J, Hsia Y, Bethel N, Park YJ, Xu C, Moyer A, Boyken SE, Ueda G, Nattermann U, Nagarajan D, Silva DA, Sheffler W, Quispe J, Nord A, King N, Bradley P, Veesler D, Kollman J, Baker D. Science 376 383-390 (2022)
  13. Lassa virus glycoprotein nanoparticles elicit neutralizing antibody responses and protection. Brouwer PJM, Antanasijevic A, Ronk AJ, Müller-Kräuter H, Watanabe Y, Claireaux M, Perrett HR, Bijl TPL, Grobben M, Umotoy JC, Schriek AI, Burger JA, Tejjani K, Lloyd NM, Steijaert TH, van Haaren MM, Sliepen K, de Taeye SW, van Gils MJ, Crispin M, Strecker T, Bukreyev A, Ward AB, Sanders RW. Cell Host Microbe 30 1759-1772.e12 (2022)
  14. Generation of ordered protein assemblies using rigid three-body fusion. Vulovic I, Yao Q, Park YJ, Courbet A, Norris A, Busch F, Sahasrabuddhe A, Merten H, Sahtoe DD, Ueda G, Fallas JA, Weaver SJ, Hsia Y, Langan RA, Plückthun A, Wysocki VH, Veesler D, Jensen GJ, Baker D. Proc Natl Acad Sci U S A 118 e2015037118 (2021)
  15. Antigen- and scaffold-specific antibody responses to protein nanoparticle immunogens. Kraft JC, Pham MN, Shehata L, Brinkkemper M, Boyoglu-Barnum S, Sprouse KR, Walls AC, Cheng S, Murphy M, Pettie D, Ahlrichs M, Sydeman C, Johnson M, Blackstone A, Ellis D, Ravichandran R, Fiala B, Wrenn S, Miranda M, Sliepen K, Brouwer PJM, Antanasijevic A, Veesler D, Ward AB, Kanekiyo M, Pepper M, Sanders RW, King NP. Cell Rep Med 3 100780 (2022)
  16. Tight nanoscale clustering of Fcγ receptors using DNA origami promotes phagocytosis. Kern N, Dong R, Douglas SM, Vale RD, Morrissey MA. Elife 10 e68311 (2021)
  17. Single-component multilayered self-assembling protein nanoparticles presenting glycan-trimmed uncleaved prefusion optimized envelope trimmers as HIV-1 vaccine candidates. Zhang YN, Paynter J, Antanasijevic A, Allen JD, Eldad M, Lee YZ, Copps J, Newby ML, He L, Chavez D, Frost P, Goodroe A, Dutton J, Lanford R, Chen C, Wilson IA, Crispin M, Ward AB, Zhu J. Nat Commun 14 1985 (2023)
  18. A Nanoscaffolded Spike-RBD Vaccine Provides Protection against SARS-CoV-2 with Minimal Anti-Scaffold Response. Lainšček D, Fink T, Forstnerič V, Hafner-Bratkovič I, Orehek S, Strmšek Ž, Manček-Keber M, Pečan P, Esih H, Malenšek Š, Aupič J, Dekleva P, Plaper T, Vidmar S, Kadunc L, Benčina M, Omersa N, Anderluh G, Pojer F, Lau K, Hacker D, Correia BE, Peterhoff D, Wagner R, Bergant V, Herrmann A, Pichlmair A, Jerala R. Vaccines (Basel) 9 431 (2021)
  19. Fast and versatile sequence-independent protein docking for nanomaterials design using RPXDock. Sheffler W, Yang EC, Dowling Q, Hsia Y, Fries CN, Stanislaw J, Langowski MD, Brandys M, Li Z, Skotheim R, Borst AJ, Khmelinskaia A, King NP, Baker D. PLoS Comput Biol 19 e1010680 (2023)
  20. De novo design of protein homodimers containing tunable symmetric protein pockets. Hicks DR, Kennedy MA, Thompson KA, DeWitt M, Coventry B, Kang A, Bera AK, Brunette TJ, Sankaran B, Stoddard B, Baker D. Proc Natl Acad Sci U S A 119 e2113400119 (2022)
  21. Co-display of diverse spike proteins on nanoparticles broadens sarbecovirus neutralizing antibody responses. Brinkkemper M, Veth TS, Brouwer PJM, Turner H, Poniman M, Burger JA, Bouhuijs JH, Olijhoek W, Bontjer I, Snitselaar JL, Caniels TG, van der Linden CA, Ravichandran R, Villaudy J, van der Velden YU, Sliepen K, van Gils MJ, Ward AB, King NP, Heck AJR, Sanders RW. iScience 25 105649 (2022)
  22. Improving the secretion of designed protein assemblies through negative design of cryptic transmembrane domains. Wang JYJ, Khmelinskaia A, Sheffler W, Miranda MC, Antanasijevic A, Borst AJ, Torres SV, Shu C, Hsia Y, Nattermann U, Ellis D, Walkey C, Ahlrichs M, Chan S, Kang A, Nguyen H, Sydeman C, Sankaran B, Wu M, Bera AK, Carter L, Fiala B, Murphy M, Baker D, Ward AB, King NP. Proc Natl Acad Sci U S A 120 e2214556120 (2023)
  23. Antigen spacing on protein nanoparticles influences antibody responses to vaccination. Ellis D, Dosey A, Boyoglu-Barnum S, Park YJ, Gillespie R, Syeda H, Hutchinson GB, Tsybovsky Y, Murphy M, Pettie D, Matheson N, Chan S, Ueda G, Fallas JA, Carter L, Graham BS, Veesler D, Kanekiyo M, King NP. Cell Rep 42 113552 (2023)
  24. Comparative Immunogenicity of Bacterially Expressed Soluble Trimers and Nanoparticle Displayed Influenza Hemagglutinin Stem Immunogens. Kar U, Khaleeq S, Garg P, Bhat M, Reddy P, Vignesh VS, Upadhyaya A, Das M, Chakshusmathi G, Pandey S, Dutta S, Varadarajan R. Front Immunol 13 890622 (2022)
  25. Nanoparticle display of prefusion coronavirus spike elicits S1-focused cross-reactive antibody response against diverse coronavirus subgenera. Hutchinson GB, Abiona OM, Ziwawo CT, Werner AP, Ellis D, Tsybovsky Y, Leist SR, Palandjian C, West A, Fritch EJ, Wang N, Wrapp D, Boyoglu-Barnum S, Ueda G, Baker D, Kanekiyo M, McLellan JS, Baric RS, King NP, Graham BS, Corbett-Helaire KS. Nat Commun 14 6195 (2023)
  26. Polysaccharide Nanoparticles from Isatis indigotica Fort. Root Decoction: Diversity, Cytotoxicity, and Antiviral Activity. Gao G, He C, Wang H, Guo J, Ke L, Zhou J, Chong PH, Rao P. Nanomaterials (Basel) 12 30 (2021)
  27. A fragment-based protein interface design algorithm for symmetric assemblies. Laniado J, Meador K, Yeates TO. Protein Eng Des Sel 34 gzab008 (2021)
  28. Design of functionalised circular tandem repeat proteins with longer repeat topologies and enhanced subunit contact surfaces. Hallinan JP, Doyle LA, Shen BW, Gewe MM, Takushi B, Kennedy MA, Friend D, Roberts JM, Bradley P, Stoddard BL. Commun Biol 4 1240 (2021)
  29. Synthetic vaccine affords full protection to mice against lethal challenge of influenza B virus of both genetic lineages. Gravel C, Muralidharan A, Duran A, Zetner A, Pfeifle A, Zhang W, Hashem A, Tamming L, Farnsworth A, Loemba H, Chen W, Krammer F, Safronetz D, Cao J, Wang L, Sauve S, Rosu-Myles M, Van Domselaar G, Li X. iScience 24 103328 (2021)
  30. The role of oligomerization in the optimization of cyclohexadienyl dehydratase conformational dynamics and catalytic activity. East NJ, Clifton BE, Jackson CJ, Kaczmarski JA. Protein Sci 31 e4510 (2022)
  31. Design and immunological evaluation of two-component protein nanoparticle vaccines for East Coast fever. Lacasta A, Kim HC, Kepl E, Gachogo R, Chege N, Ojuok R, Muriuki C, Mwalimu S, Touboul G, Stiber A, Poole EJ, Ndiwa N, Fiala B, King NP, Nene V. Front Immunol 13 1015840 (2022)
  32. Rapid and automated design of two-component protein nanomaterials using ProteinMPNN. de Haas RJ, Brunette N, Goodson A, Dauparas J, Yi SY, Yang EC, Dowling Q, Nguyen H, Kang A, Bera AK, Sankaran B, de Vries R, Baker D, King NP. Proc Natl Acad Sci U S A 121 e2314646121 (2024)
  33. De novo design of modular protein hydrogels with programmable intra- and extracellular viscoelasticity. Mout R, Bretherton RC, Decarreau J, Lee S, Gregorio N, Edman NI, Ahlrichs M, Hsia Y, Sahtoe DD, Ueda G, Sharma A, Schulman R, DeForest CA, Baker D. Proc Natl Acad Sci U S A 121 e2309457121 (2024)
  34. Immunogenicity and protective efficacy of GBP510/AS03 vaccine against SARS-CoV-2 delta challenge in rhesus macaques. Jacob-Dolan C, Yu J, McMahan K, Giffin V, Chandrashekar A, Martinot AJ, Anioke T, Powers OC, Hall K, Hope D, Miller J, Hachmann NP, Chung B, Gardner S, Sellers D, Barrett J, Lewis MG, Andersen H, Kleanthous H, Seo KW, Lee SJ, Park YW, Kim H, Barouch DH. NPJ Vaccines 8 23 (2023)
  35. Pan-neutralizing, germline-encoded antibodies against SARS-CoV-2: Addressing the long-term problem of escape variants. Lunderberg JM, Dutta S, Collier AY, Lee JS, Hsu YM, Wang Q, Zheng W, Hao S, Zhang H, Feng L, Robson SC, Gao W, Riedel S. Front Immunol 13 1032574 (2022)
  36. Structural characterisation of hemagglutinin from seven Influenza A H1N1 strains reveal diversity in the C05 antibody recognition site. Ghafoori SM, Petersen GF, Conrady DG, Calhoun BM, Stigliano MZZ, Baydo RO, Grice R, Abendroth J, Lorimer DD, Edwards TE, Forwood JK. Sci Rep 13 6940 (2023)
  37. A suite of designed protein cages using machine learning and protein fragment-based protocols. Meador K, Castells-Graells R, Aguirre R, Sawaya MR, Arbing MA, Sherman T, Senarathne C, Yeates TO. Structure 32 751-765.e11 (2024)
  38. Facile Synthesis of Peptide-Conjugated Gold Nanoclusters with Different Lengths. Ma Q, Liu L, Yang Z, Zheng P. Nanomaterials (Basel) 11 2932 (2021)
  39. Intranasal SARS-CoV-2 RBD decorated nanoparticle vaccine enhances viral clearance in the Syrian hamster model. Patel DR, Minns AM, Sim DG, Field CJ, Kerr AE, Heinly TA, Luley EH, Rossi RM, Bator CM, Moustafa IM, Norton EB, Hafenstein SL, Lindner SE, Sutton TC. Microbiol Spectr 12 e0499822 (2024)
  40. An interaction network approach predicts protein cage architectures in bionanotechnology. Fatehi F, Twarock R. Proc Natl Acad Sci U S A 120 e2303580120 (2023)
  41. In vivo selection of synthetic nucleocapsids for tissue targeting. Olshefsky A, Benasutti H, Sylvestre M, Butterfield GL, Rocklin GJ, Richardson C, Hicks DR, Lajoie MJ, Song K, Leaf E, Treichel C, Decarreau J, Ke S, Kher G, Carter L, Chamberlain JS, Baker D, King NP, Pun SH. Proc Natl Acad Sci U S A 120 e2306129120 (2023)
  42. Self-Assembling Nanoparticle Hemagglutinin Influenza Vaccines Induce High Antibody Response. Ren H, Zhang B, Zhang X, Wang T, Hou X, Lan X, Pan C, Wu J, Liu B. Int J Mol Sci 25 7259 (2024)


Quick links